Frye, Björn C. http://orcid.org/0000-0003-3520-1868
Gaede, Karoline I.
Saltini, Cesare
Rossman, Milton D.
Monos, Dimitri S.
Rosenman, Ken D.
Schuler, Christine R.
Weston, Ainsley
Wegner, Ralf
Noth, Rainer
Zissel, Gernot
Schreiber, Stefan
Nothnagel, Michael
Müller-Quernheim, Joachim
Funding for this research was provided by:
Deutscher Forschungsgemeinschaft / German Research Foundation (Mu692/7-1)
Article History
Received: 14 December 2020
Accepted: 22 March 2021
First Online: 16 April 2021
Declarations
:
: The main ethical approval was obtained by the Ethic Committee of the University of Freiburg, Germany, No. 80/04. All participants gave informed consent to data analyses including genetic analyses, when they agreed to the source studies.
: All participants gave informed consent to participate at the soruce studies. The manuscript does not contain any individual details of participants.
: BCF received speaker and consultant fees by Actelion, Boehringer Ingelheim, Novartis and Roche outside the submitted work. BCF acts as a consultant to and is shareholder of Advita Lifescience GmbH. KIG indicates funding of the German Research Counsil (DFG) related to project. CS has nothing to disclose. MDR has nothing to disclose. DSM acts as a consultant to, receives royalities from and owns options of Omixon. KDR has nothing to disclose.CSR has nothing to disclose. AW has nothing to disclose. RW has nothing to disclose. RN has nothing to disclose. GZ has nothing to disclose. StSch has nothing to disclose. MN has nothing to disclose. JMQ reports personal fees from Novartis, personal fees from Roche, personal fees and other from Advita Lifescience GmbH, outside the submitted work